Southern California Dermatology, Inc. | Santa Ana, CA

Research site

(Unclaimed)

Location

1125 East 17th St Suite W248-244, Santa Ana, California, United States of America

Site insights

Top conditions

Top treatments

Baricitinib

Guselkumab

Tirzepatide

LY3009104

LY3298176

PF-06651600

JNJ-77242113

CB-03-01

Amlitelimab

BI 730357

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 43 total trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (REIMAGINE 1)

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new invest...

Active, not recruiting

Type 2 Diabetes

Drug: Semaglutide

Drug: Placebo

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling

Hair Diseases

Alopecia

Drug: Placebo

Drug: Baricitinib

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting

Plaque Psoriasis

Drug: Deucravacitinib Matching Placebo

Drug: JNJ-77242113 Matching Placebo

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting

Plaque Psoriasis

Drug: JNJ-77242113

Drug: Placebo

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

Active, not recruiting

Overweight

Obesity

Drug: Tirzepatide

Drug: Placebo

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Orforglipron

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting

Plaque Psoriasis

Drug: Ustekinumab

Drug: Matching Placebo to Ustekinumab

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Active, not recruiting

Dermatitis Atopic

Drug: Topical calcineurin inhibitors

Drug: Amlitelimab

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (IMMpactful)

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting

Moderate Plaque Psoriasis

Drug: Risankizumab

Drug: Deucravacitinib

Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescen...

Active, not recruiting

Alopecia Areata

Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Enrolling

Atopic Dermatitis

Drug: Placebo

Drug: GHZ339

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg